Latest news
Stories
How we did
Donate
Calendar
In touch
What do you need from AGSD-UK?
Have you read the latest news?
Update on Pompe Disease Treatment.
Avalglucosidase-alfa was awarded EAMS (Early Access to Medicines Status) in February 2021.
RCPCH &Us Rare Disease Survey.
RCPCH &Us have a survey for children & young people aged 13-25, who have a rare disease & live in the UK.
Aldwyn Cooper 1949 – 2021.
We are sad to report that AGSD-UK member Aldwyn Cooper has passed away.
Trial: Seroprevalence study in Pompe disease.
The John Walton Muscular Dystrophy Research Centre in Newcastle is running a new study in Pompe disease.
Rare Disease Day 2021
2 days to go until Rare Disease Day 2021.
Eurordis H-Care Survey of rare diseases results.
Eurordis key findings from a survey on patients’ and carers’
experience of medical care for their rare diseases.
Winner announced of the PST Avatar Competition.
The Pompe Support Team wanted to create a fun opportunity for children, as a show of support during lockdown.
Spark Therapeutics doses the first participant in Gene Therapy trial.
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease
Use the scroll links to move back and fore through our news stories.
If you have a GSD news story message us or see Notes for contributors.
Read some personal stories
Do you have an interesting personal story to tell? Just message us or visit the Notes for contributors.
For personal stories on an individual GSD, visit the page for that GSD.
What and who we are
- National support group for those affected by Glycogen Storage Disease (GSD) and their families.
- Membership based with an elected board of trustees.
- A company limited by guarantee and a registered charity.
- Collaborators with UK rare disease and international GSD groups.
Keep in touch
Register FREE with AGSD-UK to keep in touch with the latest developments and future conferences, workshops, courses and fundraising events. It helps you keep in touch with other patients and families. You will receive our magazine, Glisten, by email.